CCM
FLNA

CAAS Capital Management’s Filana Therapeutics FLNA Stock Holding History

CAAS Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-687,260
Closed -$4.69M – 1365
2020
Q4 		$4.69M Buy
+687,260
New +$6.14M 0.04% 334

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAAS Capital Management's FLNA Position: Q1 2021 in Review

CAAS Capital Management sold out of Filana Therapeutics (FLNA) in Q1 2021, closing a stake of 687,260 shares — an estimated $4.69M sold.

CAAS Capital Management first reported a position in FLNA in Q4 2020 and held it in 1 quarter. The position peaked at $4.69M in Q4 2020. 128 funds tracked by Wall St. Rank hold FLNA as of Q1 2021.

  • CAAS Capital Management reported no remaining Filana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 687,260 Filana Therapeutics shares in Q1 2021, an estimated $4.69M.
  • CAAS Capital Management first reported a position in Filana Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Filana Therapeutics position peaked at $4.69M in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.